OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Immunology Immunotherapy is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML c	132
Host B cells escape CAR-T immunotherapy by reversible downregulation of CD19	122
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study	119
A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma	119
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma	100
A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model	61
Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells	58
A nanotherapeutic system for gastric cancer suppression by synergistic chemotherapy and immunotherapy based on iPSCs and DCs exosomes	55
Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter ret	53
Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer	52
Tumor-associated macrophages as a potential therapeutic target in thyroid cancers	52
Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies	52
Cytokine alterations during paraneoplastic neutrophilia and leukemoid reaction in patients with advanced melanoma	43
Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and m	42
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study	40
Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition	40
Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist	39
Bis-indole-derived NR4A1 antagonists inhibit colon tumor and splenic growth and T-cell exhaustion	39
Reovirus combined with a STING agonist enhances anti-tumor immunity in a mouse model of colorectal cancer	38
Endosialin-positive tumor-derived pericytes promote tumor progression through impeding the infiltration of CD8+ T cells in clear cell renal cell carcinoma	38
Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors	37
Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas	37
Costimulatory molecule expression profile as a biomarker to predict prognosis and chemotherapy response for patients with small cell lung cancer	37
Systemic administration of STING agonist promotes myeloid cells maturation and antitumor immunity through regulating hematopoietic stem and progenitor cell fate	35
Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents	35

Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens	35
A retrospective real-world study: the efficacy of immune-related combination therapies in advanced non-small cell lung cancer after resistance to EGFR-TKIs	34
GK-1 effectively reduces angiogenesis and prevents T cell exhaustion in a breast cancer murine experimental model	34
Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinoma	33
TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors	33
Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells	32
Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma	32
Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy	32